Kura Oncology, Inc. (KURA)
12.89
+0.24
(+1.90%)
USD |
NASDAQ |
Sep 01, 15:48
Kura Oncology Total Long Term Debt (Quarterly) : 23.16M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 23.16M |
| March 31, 2026 | 22.99M |
| December 31, 2025 | 19.18M |
| September 30, 2025 | 18.04M |
| June 30, 2025 | 17.78M |
| March 31, 2025 | 17.45M |
| December 31, 2024 | 14.71M |
| September 30, 2024 | 14.94M |
| June 30, 2024 | 15.27M |
| March 31, 2024 | 15.61M |
| December 31, 2023 | 15.69M |
| September 30, 2023 | 15.74M |
| June 30, 2023 | 10.70M |
| March 31, 2023 | 11.21M |
| December 31, 2022 | 11.71M |
| September 30, 2022 | 3.08M |
| June 30, 2022 | 3.602M |
| March 31, 2022 | 4.114M |
| December 31, 2021 | 4.612M |
| September 30, 2021 | 5.103M |
| June 30, 2021 | 4.755M |
| March 31, 2021 | 11.70M |
| December 31, 2020 | 12.89M |
| Date | Value |
|---|---|
| September 30, 2020 | 13.52M |
| June 30, 2020 | 13.52M |
| March 31, 2020 | 9.30M |
| December 31, 2019 | 7.50M |
| September 30, 2019 | 7.50M |
| June 30, 2019 | 7.523M |
| March 31, 2019 | 7.614M |
| December 31, 2018 | 7.50M |
| September 30, 2018 | 6.266M |
| June 30, 2018 | 6.963M |
| March 31, 2018 | 7.155M |
| December 31, 2017 | 7.098M |
| September 30, 2017 | 7.042M |
| June 30, 2017 | 7.355M |
| March 31, 2017 | 7.339M |
| December 31, 2016 | 7.324M |
| September 30, 2016 | 7.308M |
| June 30, 2016 | 7.292M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | 5.103M |
| Fortress Biotech, Inc. | 46.07M |
| Syndax Pharmaceuticals, Inc. | 588.88M |
| Spero Therapeutics, Inc. | 0.043M |
| Gossamer Bio, Inc. | 39.10M |